GSK, Sanofi, Haleon shares stabilise after Zantac slump Shares in GSK, Sanofi and Haleon began to stabilise today after the companies said that nothing material had changed regarding US litigation focused on heartburn … Business • 12 Aug
Pfizer buys Global Blood Therapeutics for $5.4 bilion Pfizer is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to … Business • 08 Aug
Pfizer profit surges, reaffirms sales forecast Pfizer has reported a 78% jump in profit and reaffirmed the combined 2022 sales forecast of $54 billion for its Covid-19 vaccine and pill as … Business • 28 Jul
Pfizer asks for US approval of Covid treatment Paxlovid Pfizer has said it is seeking full US approval for its oral Covid-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorisation. World • 30 Jun
Pfizer to buy 8.1% stake in vaccines company Valneva US healthcare giant Pfizer has agreed to invest €90.5 million to buy an 8.1% percent stake in French vaccines company, as the companies announced developments … Business • 20 Jun
Pfizer to buy Biohaven Pharmaceutical for $11.6 billion Pfizer said it will buy migraine drug maker Biohaven Pharmaceutical Holding Company for about $11.6 billion in cash, as the drugmaker seeks to beef up … Business • 10 May
Pfizer keeps forecasts for Covid pill, vaccine steady Pfizer has today maintained sales forecasts for its Covid products after a series of hikes to the sales outlook for its Covid-19 vaccine last year, … Business • 03 May
Pfizer, Bayer to maintain drug supply to Russia Pfizer and Bayer have said they will maintain humanitarian supply of medicines to Russia, but would pull back from other non-essential spending in the country. Business • 14 Mar
GSK to name consumer healthcare unit 'Haleon' GlaxoSmithKline said today that its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off … Business • 22 Feb
Pfizer forecasts $54bn in Covid vaccine, pill sales Pfizer's forecast for full-year sales of its Covid-19 vaccine and antiviral pill fell short of lofty Wall Street estimates today, sending the drugmaker's shares down … Business • 08 Feb
BioNTech expects up to €17bn in vaccine revenue in 2022 BioNTech has said it would likely generate up to €17 billion in 2022 revenue from the Covid-19 vaccine it co-developed with Pfizer, pledging to spend … Business • 11 Jan
France cancels order for Merck's Covid-19 drug France has cancelled its order for Merck & Co's Covid-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before … Business • 22 Dec 21
Pfizer raises Covid vaccine sales forecast to $36bn Pfizer has today forecast better-than-expected $29 billion in sales from its Covid-19 vaccine for 2022 and said t was seeking to sign more deals with … Business • 02 Nov 21
Pfizer vaccine 'highly effective' against severe Covid Vaccination with two doses of the Pfizer jab stays highly effective against severe Covid - including the Delta variant - for at least six months, … Coronavirus • 05 Oct 21
EMA to decide on Pfizer booster vaccine on Monday The EMA will decide on Monday whether to approve Pfizer's Covid-19 booster vaccine, but it is unlikely to give precise guidance on who should receive … Coronavirus • 29 Sep 21
US FDA grants Pfizer Covid-19 vaccine full approval The US drug regulator has granted full approval to the Pfizer/BioNTech Covid-19 vaccine, making it the first to secure such Food and Drug Administration validation … Coronavirus • 23 Aug 21
Pfizer, Moderna could reap billions from booster shots Drugmakers Pfizer, BioNTech and Moderna are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion … Business • 13 Aug 21
Pfizer and Moderna raise vaccine prices in EU - report Pfizer and Moderna have raised the prices of their Covid-19 vaccines in the latest European Union supply contracts, according to a report in The Financial … Coronavirus • 01 Aug 21
Pfizer raises forecast for Covid vaccine sales Pfizer has raised its forecast for sales of the Covid-19 vaccine that it developed with Germany's BioNTech by 28.8% to $33.5 billion, as countries scramble … Business • 28 Jul 21
GSK's drugs arm to get £8 billion booster from spin-off GSK has set out its plans to turn its consumer healthcare arm into a separately listed company, in a move that will deliver an £8 … Business • 24 Jun 21
US to donate 500 million vaccines to poorest countries US President Joe Biden has pledged that America will be the "arsenal of vaccines, as it was the arsenal of democracy in World War II" … Coronavirus • 10 Jun 21
Pfizer lifts sales forecast for Covid vaccine to $26bn Pfizer has forecast $26 billion in Covid-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments … Business • 04 May 21
EU looks to secure 1.8bn 2nd-generation vaccine doses The EU is about to start negotiations with a single pharmaceutical company to secure up to 1.8 billion doses of a "second generation" mRNA vaccine … Coronavirus • 09 Apr 21
Pfizer, BioNTech say jab can stand warmer temperatures BioNTech and its US partner Pfizer have said tests have shown that their Covid-19 vaccine can stand warmer temperatures than initially thought, potentially simplifying the … Coronavirus • 19 Feb 21
EU buys up to 300 million more Moderna jabs The European Commission has said it had struck a deal for an extra 150 million doses of Moderna's Covid-19 vaccine this year, nearly doubling the … World • 17 Feb 21
